DAPT De Escalation Strategy Calculator Ticagrelor or Prasugrel to Clopidogrel
Clinical decision inputs
Enter the patient's post-PCI status to organize factors relevant to P2Y12 inhibitor de-escalation.
Clinical context
For patients with ACS undergoing PCI, aspirin plus an oral P2Y12 inhibitor is the default antiplatelet strategy for 12 months when bleeding risk is not high. Ticagrelor or prasugrel is generally preferred to clopidogrel in ACS patients undergoing PCI when suitable. The 2025 ACC/AHA ACS guideline states that switching from ticagrelor or prasugrel to clopidogrel after 1 month may be reasonable in selected patients to reduce bleeding risk.
Evidence for de-escalation comes from trials with specific populations and protocols. TALOS-AMI studied stabilized patients with myocardial infarction who had no major ischemic or bleeding events during the first month after PCI; TROPICAL-ACS evaluated a platelet-function-guided step-down strategy from prasugrel. These findings should not be generalized automatically to every patient, every P2Y12 inhibitor, or unstable patients.
How to use this tool
- Use it to organize a clinical review, not to prescribe, switch, or interrupt antiplatelet treatment automatically.
- Assess bleeding and ischemic risk, clinical stability, adherence, coronary anatomy, comorbidities, drug interactions, and patient preferences.
- For patients receiving oral anticoagulation, review the entire antithrombotic regimen and aspirin duration separately.
- Major bleeding, recurrent ischemia, or suspected stent thrombosis requires prompt clinical assessment.
References
J Am Coll Cardiol. DOI: 10.1016/j.jacc.2024.11.009
Lancet. 2021;398:1305-1316. PMID: 34627490. DOI: 10.1016/S0140-6736(21)01445-8
Lancet. 2017;390:1747-1757. PMID: 28855078. DOI: 10.1016/S0140-6736(17)32155-4
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.